Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 7/20 | 0.59 |
| ▸ | METAP1 | P53582 | 4/20 | 0.49 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | CES1 | P23141 | 1/20 | 0.41 |
| ▸ | MAOA | P21397 | 1/20 | 0.41 |
| ▸ | HTR1A | P08908 | 1/20 | 0.40 |
| ▸ | DRD2 | P14416 | 1/20 | 0.40 |
| ▸ | HTR2A | P28223 | 1/20 | 0.40 |
| ▸ | HTR2C | P28335 | 1/20 | 0.40 |
| ▸ | HTR7 | P34969 | 1/20 | 0.40 |
| ▸ | HRH1 | P35367 | 1/20 | 0.40 |
| ▸ | DRD3 | P35462 | 1/20 | 0.40 |
| ▸ | HTR2B | P41595 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29865183 | 1.00 | ACHE (0.59) | ACHEMETAP1CYP19A1TSHRSMN1; SMN2 | |
| SCHEMBL669071 | 0.79 | CYP19A1 (0.51) | ACHECYP19A1TSHRSMN1; SMN2KDM4E | |
| SCHEMBL31278320 | 0.79 | CYP19A1 (0.51) | ACHECYP19A1TSHRSMN1; SMN2KDM4E | |
| SCHEMBL5539639 | 0.77 | ACHE (0.63) | ACHEMETAP1CYP19A1TSHRSMN1; SMN2 | |
| SCHEMBL14157895 | 0.77 | ACHE (0.63) | ACHEMETAP1CYP19A1TSHRSMN1; SMN2 | |
| SCHEMBL12500873 | 0.76 | CYP2A6 (0.50) | ACHECYP19A1TSHRKDM4EMAPT | |
| SCHEMBL16425772 | 0.76 | MAOA (0.55) | ACHETSHRKDM4EMEN1KMT2A | |
| SCHEMBL11818087 | 0.76 | ACHE (0.61) | ACHEMETAP1CYP19A1TSHRSMN1; SMN2 | |
| SCHEMBL9752693 | 0.74 | ACHE (1.00) | ACHEMETAP1CYP19A1TSHR | |
| SCHEMBL7560591 | 0.74 | HTR2A (0.53) | ACHETSHRSMN1; SMN2KDM4EMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 53 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4729508-A1 | TETRALIN AND TETRAHYDROQUINOLINE COMPOUNDS AS INHIBITORS OF HIF-2ALPHA | Arcus Biosciences, Inc. (US) | 2026-04-22 | — | — | EP | disclosed |
| US-20250214930-A1 | TETRALIN AND TETRAHYDROQUINOLINE COMPOUNDS AS INHIBITORS OF HIF-2ALPHA | ARCUS BIOSCIENCES, INC. (US) | 2025-07-03 | — | — | US | disclosed |
| US-12103907-B2 | Tetralin and tetrahydroquinoline compounds as inhibitors of HIF-2alpha | ARCUS BIOSCIENCES, INC. (US) | 2024-10-01 | — | — | US | disclosed |
| US-20240254079-A1 | TETRALIN AND TETRAHYDROQUINOLINE COMPOUNDS AS INHIBITORS OF HIF-2ALPHA | ARCUS BIOSCIENCES, INC. | 2024-08-01 | — | — | US | disclosed |
| WO-2024067463-A1 | BENZO[7]ANNULENE DERIVATIVE, PHARMACEUTICAL COMPOSITION COMPRISING SAME, AND MEDICAL USES THEREOF | 苏州阿尔脉生物科技有限公司 | 2024-04-04 | — | — | WO | disclosed |
| CN-117126126-A | Method for asymmetrically synthesizing adjacent halohydrin compound | 凯特立斯（深圳）科技有限公司 | 2023-11-28 | — | — | CN | disclosed |
| US-11787762-B2 | Tetralin and tetrahydroquinoline compounds as inhibitors of HIF-2alpha | ARCUS BIOSCIENCES, INC. (US) | 2023-10-17 | — | — | US | disclosed |
| CN-112250708-B | Anthracene-containing dimer skeleton ligand, preparation method thereof and application thereof in metal catalytic reaction | 中国科学院理化技术研究所 | 2023-10-13 | — | — | CN | disclosed |
| US-20230021476-A1 | TETRALIN AND TETRAHYDROQUINOLINE COMPOUNDS AS INHIBITORS OF HIF-2ALPHA | ARCUS BIOSCIENCES, INC. | 2023-01-26 | — | — | US | disclosed |
| EP-4121409-A1 | TETRALIN AND TETRAHYDROQUINOLINE COMPOUNDS AS INHIBITORS OF HIF-2ALPHA | Arcus Biosciences, Inc. (US) | 2023-01-25 | — | — | EP | disclosed |
| US-20030153609-A1 | C2-disubstituted indan-1-ones and their derivatives, processes for their preparation and their use as pharmaceuticals | AVENTIS PHARMA DUTSCHLAN GMBH. | 2003-08-14 | — | — | US | disclosed |
| CN-1113874-C | Benzocycloalkylazolethione derivatives | SYNTEX INC (US) | 2003-07-09 | — | — | CN | disclosed |
| WO-2003020697-A1 | C2-DISUBSTITUTED INDANE-1-ONES AND THEIR DERIVATIVES, METHOD FOR THEIR PRODUCTION AND THEIR USE AS MEDICAMENTS | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2003-03-13 | — | — | WO | disclosed |
| CN-1151735-A | Benzocycloalkylazolethione derivatives | SYNTEX INC (US) | 1997-06-11 | — | — | CN | disclosed |
| US-5153211-A | Enzyme inhibitors | ALCON LABORATORIES, INC. (US) | 1992-10-06 | — | — | US | disclosed |
| US-5070100-A | COMPLICATIONS OF DIABETES | ALCON LABORATORIES, INC. (US) | 1991-12-03 | — | — | US | disclosed |
| US-4864028-A | ANTIDIABETIC AGENTS | ALCON LABORATORIES, INC. (US) | 1989-09-05 | — | — | US | disclosed |
| EP-0314400-A1 | Therapeutically active condensed thiadiazinones | SMITH KLINE & FRENCH LABORATORIES LIMITED (GB) | 1989-05-03 | — | — | EP | disclosed |
| US-4537892-A | ANTIDIABETIC AGENTS | ALCON LABORATORIES, INC. (US) | 1985-08-27 | — | — | US | disclosed |
| EP-0137333-A2 | Spiro-tricyclicaromatic succinimide derivatives as inhibitors of aldose reductase | ALCON LABORATORIES, INC. (US) | 1985-04-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250214930-A1 | TETRALIN AND TETRAHYDROQUINOLINE COMPOUNDS AS INHIBITORS OF HIF-2ALPHA | HIF1AN, HIF1A, EGLN2 | ACHE 4884/4885METAP1 3367/4885CYP19A1 796/4885 |
| US-20240254079-A1 | TETRALIN AND TETRAHYDROQUINOLINE COMPOUNDS AS INHIBITORS OF HIF-2ALPHA | HIF1AN, HIF1A, EGLN2 | ACHE 4884/4885METAP1 3367/4885CYP19A1 796/4885 |
| US-20030153609-A1 | C2-disubstituted indan-1-ones and their derivatives, processes for their preparation and their use as pharmaceuticals | GPR119, INSR, IRS1 | ACHE 2620/4885METAP1 775/4885CYP19A1 98/4885 |
| US-11787762-B2 | Tetralin and tetrahydroquinoline compounds as inhibitors of HIF-2alpha | HIF1AN, HIF1A, EGLN2 | ACHE 4884/4885METAP1 3367/4885CYP19A1 796/4885 |
| US-20230021476-A1 | TETRALIN AND TETRAHYDROQUINOLINE COMPOUNDS AS INHIBITORS OF HIF-2ALPHA | HIF1AN, HIF1A, EGLN2 | ACHE 4884/4885METAP1 3367/4885CYP19A1 796/4885 |
| US-12103907-B2 | Tetralin and tetrahydroquinoline compounds as inhibitors of HIF-2alpha | HIF1AN, HIF1A, EGLN2 | ACHE 4884/4885METAP1 3367/4885CYP19A1 796/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.